passagebio.com (PASG): רווח נקי למניה (EPS TTM)

Unique treatments for pediatric CNS pathologies provide Passage Bio, Inc. (PASG) with high margins. Monopoly market access via patents guarantees business scalability, although high development costs create a liquidity deficit. The TTM net income per share snapshot clearly demonstrates these financial fluctuations, with the parameter value equal to -11.37, which is critical for portfolio risk assessment.

Passage Bio, Inc. (PASG) occupies a niche in high-tech gene therapy for rare CNS pathologies. This metric reflects the actual profit share per security over a rolling year. Analyzing net income per share over the last 12 months allows for an assessment of capital efficiency in R&D. This chart reveals the impact of viral vector costs on final profitability. This is a key indicator of the long-term financial sustainability of the biopharmaceutical business.